Trials Sponsors Conditions Drugs Pricing

Conditions

Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Carcinoma

Outcome Measures

Primary Outcomes (2)

Cohort 1 - Cancer-related fatigue
Cancer-related fatigue will be measured using the Fatigue Symptom Inventory. The scale is composed of 14 items (one is not scored). A total Disruption Index is calculated by summing items 5-11 (each item ranges from 0-10). A lower score indicates lower fatigue. Possible range is 0-70.
post treatment
Cohort 2 - Recurrence-free survival
Time from diagnosis to first known recurrence or death, censored at least follow-up if recurrence free and alive
3 years

Study Arms (2)

Cohort 1 - Cross-sectional (within 2 years of diagnosis)

Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure

Cohort 2- Prospective (from diagnosis)

Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Individuals diagnosed and/or treated for ovarian/Fallopian tube/primary peritoneal cancer by physicians in the Gynecologic Oncology Clinic at the University of Minnesota

You may qualify if:

Age ≥18

Sponsors & Collaborators

University of Minnesota
Otherlead
United States Department of Defense
US federal agencycollaborator

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples at up to 3 time points

MeSH Terms

Conditions

Ovarian NeoplasmsFallopian Tube Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System Diseases

Enrollment

255 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 16, 2019

First Posted

April 19, 2019

Study Start

October 22, 2019

Actual (reported)

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (2)

Cohort 1 - Cross-sectional (within 2 years of diagnosis)

Cohort 2- Prospective (from diagnosis)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (2)

Cohort 1 - Cross-sectional (within 2 years of diagnosis)

Cohort 2- Prospective (from diagnosis)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations